TP53 and cancer: Intriguingly, in contrast with most human cancer types exhibiting an oncogenic Myc activation, primary NBs rarely display p53 mutations, and deletions or loss of heterozygosity (LOH) at 17p (where p53 maps) are uncommon (Vogan et al, 1993).